Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening.

<h4>Background</h4>Praziquantel (PZQ) is the only widely available drug to treat schistosomiasis. Given the potential for drug resistance, it is prudent to search for novel therapeutics. Identification of anti-schistosomal chemicals has traditionally relied on phenotypic (whole organism)...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Maha-Hamadien Abdulla, Debbie S Ruelas, Brian Wolff, June Snedecor, Kee-Chong Lim, Fengyun Xu, Adam R Renslo, Janice Williams, James H McKerrow, Conor R Caffrey
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2009
Materias:
Acceso en línea:https://doaj.org/article/e07426d1155142edb442dafbc6846ea9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:e07426d1155142edb442dafbc6846ea9
record_format dspace
spelling oai:doaj.org-article:e07426d1155142edb442dafbc6846ea92021-11-25T06:33:17ZDrug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening.1935-27271935-273510.1371/journal.pntd.0000478https://doaj.org/article/e07426d1155142edb442dafbc6846ea92009-07-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19597541/?tool=EBIhttps://doaj.org/toc/1935-2727https://doaj.org/toc/1935-2735<h4>Background</h4>Praziquantel (PZQ) is the only widely available drug to treat schistosomiasis. Given the potential for drug resistance, it is prudent to search for novel therapeutics. Identification of anti-schistosomal chemicals has traditionally relied on phenotypic (whole organism) screening with adult worms in vitro and/or animal models of disease-tools that limit automation and throughput with modern microtiter plate-formatted compound libraries.<h4>Methods</h4>A partially automated, three-component phenotypic screen workflow is presented that utilizes at its apex the schistosomular stage of the parasite adapted to a 96-well plate format with a throughput of 640 compounds per month. Hits that arise are subsequently screened in vitro against adult parasites and finally for efficacy in a murine model of disease. Two GO/NO GO criteria filters in the workflow prioritize hit compounds for tests in the animal disease model in accordance with a target drug profile that demands short-course oral therapy. The screen workflow was inaugurated with 2,160 chemically diverse natural and synthetic compounds, of which 821 are drugs already approved for human use. This affords a unique starting point to 'reposition' (re-profile) drugs as anti-schistosomals with potential savings in development timelines and costs.<h4>Findings</h4>Multiple and dynamic phenotypes could be categorized for schistosomula and adults in vitro, and a diverse set of 'hit' drugs and chemistries were identified, including anti-schistosomals, anthelmintics, antibiotics, and neuromodulators. Of those hits prioritized for tests in the animal disease model, a number of leads were identified, one of which compares reasonably well with PZQ in significantly decreasing worm and egg burdens, and disease-associated pathology. Data arising from the three components of the screen are posted online as a community resource.<h4>Conclusions</h4>To accelerate the identification of novel anti-schistosomals, we have developed a partially automated screen workflow that interfaces schistosomula with microtiter plate-formatted compound libraries. The workflow has identified various compounds and drugs as hits in vitro and leads, with the prescribed oral efficacy, in vivo. Efforts to improve throughput, automation, and rigor of the screening workflow are ongoing.Maha-Hamadien AbdullaDebbie S RuelasBrian WolffJune SnedecorKee-Chong LimFengyun XuAdam R RensloJanice WilliamsJames H McKerrowConor R CaffreyPublic Library of Science (PLoS)articleArctic medicine. Tropical medicineRC955-962Public aspects of medicineRA1-1270ENPLoS Neglected Tropical Diseases, Vol 3, Iss 7, p e478 (2009)
institution DOAJ
collection DOAJ
language EN
topic Arctic medicine. Tropical medicine
RC955-962
Public aspects of medicine
RA1-1270
spellingShingle Arctic medicine. Tropical medicine
RC955-962
Public aspects of medicine
RA1-1270
Maha-Hamadien Abdulla
Debbie S Ruelas
Brian Wolff
June Snedecor
Kee-Chong Lim
Fengyun Xu
Adam R Renslo
Janice Williams
James H McKerrow
Conor R Caffrey
Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening.
description <h4>Background</h4>Praziquantel (PZQ) is the only widely available drug to treat schistosomiasis. Given the potential for drug resistance, it is prudent to search for novel therapeutics. Identification of anti-schistosomal chemicals has traditionally relied on phenotypic (whole organism) screening with adult worms in vitro and/or animal models of disease-tools that limit automation and throughput with modern microtiter plate-formatted compound libraries.<h4>Methods</h4>A partially automated, three-component phenotypic screen workflow is presented that utilizes at its apex the schistosomular stage of the parasite adapted to a 96-well plate format with a throughput of 640 compounds per month. Hits that arise are subsequently screened in vitro against adult parasites and finally for efficacy in a murine model of disease. Two GO/NO GO criteria filters in the workflow prioritize hit compounds for tests in the animal disease model in accordance with a target drug profile that demands short-course oral therapy. The screen workflow was inaugurated with 2,160 chemically diverse natural and synthetic compounds, of which 821 are drugs already approved for human use. This affords a unique starting point to 'reposition' (re-profile) drugs as anti-schistosomals with potential savings in development timelines and costs.<h4>Findings</h4>Multiple and dynamic phenotypes could be categorized for schistosomula and adults in vitro, and a diverse set of 'hit' drugs and chemistries were identified, including anti-schistosomals, anthelmintics, antibiotics, and neuromodulators. Of those hits prioritized for tests in the animal disease model, a number of leads were identified, one of which compares reasonably well with PZQ in significantly decreasing worm and egg burdens, and disease-associated pathology. Data arising from the three components of the screen are posted online as a community resource.<h4>Conclusions</h4>To accelerate the identification of novel anti-schistosomals, we have developed a partially automated screen workflow that interfaces schistosomula with microtiter plate-formatted compound libraries. The workflow has identified various compounds and drugs as hits in vitro and leads, with the prescribed oral efficacy, in vivo. Efforts to improve throughput, automation, and rigor of the screening workflow are ongoing.
format article
author Maha-Hamadien Abdulla
Debbie S Ruelas
Brian Wolff
June Snedecor
Kee-Chong Lim
Fengyun Xu
Adam R Renslo
Janice Williams
James H McKerrow
Conor R Caffrey
author_facet Maha-Hamadien Abdulla
Debbie S Ruelas
Brian Wolff
June Snedecor
Kee-Chong Lim
Fengyun Xu
Adam R Renslo
Janice Williams
James H McKerrow
Conor R Caffrey
author_sort Maha-Hamadien Abdulla
title Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening.
title_short Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening.
title_full Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening.
title_fullStr Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening.
title_full_unstemmed Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening.
title_sort drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening.
publisher Public Library of Science (PLoS)
publishDate 2009
url https://doaj.org/article/e07426d1155142edb442dafbc6846ea9
work_keys_str_mv AT mahahamadienabdulla drugdiscoveryforschistosomiasishitandleadcompoundsidentifiedinalibraryofknowndrugsbymediumthroughputphenotypicscreening
AT debbiesruelas drugdiscoveryforschistosomiasishitandleadcompoundsidentifiedinalibraryofknowndrugsbymediumthroughputphenotypicscreening
AT brianwolff drugdiscoveryforschistosomiasishitandleadcompoundsidentifiedinalibraryofknowndrugsbymediumthroughputphenotypicscreening
AT junesnedecor drugdiscoveryforschistosomiasishitandleadcompoundsidentifiedinalibraryofknowndrugsbymediumthroughputphenotypicscreening
AT keechonglim drugdiscoveryforschistosomiasishitandleadcompoundsidentifiedinalibraryofknowndrugsbymediumthroughputphenotypicscreening
AT fengyunxu drugdiscoveryforschistosomiasishitandleadcompoundsidentifiedinalibraryofknowndrugsbymediumthroughputphenotypicscreening
AT adamrrenslo drugdiscoveryforschistosomiasishitandleadcompoundsidentifiedinalibraryofknowndrugsbymediumthroughputphenotypicscreening
AT janicewilliams drugdiscoveryforschistosomiasishitandleadcompoundsidentifiedinalibraryofknowndrugsbymediumthroughputphenotypicscreening
AT jameshmckerrow drugdiscoveryforschistosomiasishitandleadcompoundsidentifiedinalibraryofknowndrugsbymediumthroughputphenotypicscreening
AT conorrcaffrey drugdiscoveryforschistosomiasishitandleadcompoundsidentifiedinalibraryofknowndrugsbymediumthroughputphenotypicscreening
_version_ 1718413713928617984